OMIC

Singular Genomics Systems, Inc. [OMIC] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

OMIC Stock Summary

Top 10 Correlated ETFs

OMIC


Top 10 Correlated Stocks

OMIC


In the News

04:05 29 Mar 2024 OMIC

Singular Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024

SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Monday, March 18, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

09:10 29 Mar 2024 OMIC

Singular Genomics Systems, Inc. (OMIC) Q3 2023 Earnings Call Transcript

Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - CEO, Founder & Chairman Dalen Meeter - CFO Conference Call Participants Dan Brennan - TD Cowen Matt Sykes - Goldman Sachs John Sourbeer - UBS Operator Greetings. Welcome to the Singular Genomics Systems, Inc. Third Quarter 2023 Earnings Conference Call.

04:22 29 Mar 2024 OMIC

Singular Genomics to Report Third Quarter 2023 Financial Results on November 14, 2023

SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2023 after the market close on Tuesday, November 14, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

11:28 29 Mar 2024 OMIC

Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now

The biotech sector never fails to offer up stocks full of massive issues at any given time. Developing novel therapeutic devices and pharmaceuticals is, after all, very expensive.

08:00 29 Mar 2024 OMIC

Singular Genomics to Present at the Gilmartin Group Emerging Growth Company Showcase

SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to participate in the virtual Gilmartin Group Emerging Growth Company Showcase.

08:27 29 Mar 2024 OMIC

Singular Genomics Systems, Inc. (OMIC) Q2 2023 Earnings Call Transcript

Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder, Chair and CEO Dalen Meeter - CFO Conference Call Participants Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Operator Good day, everyone, and welcome to the Singular Genomics Systems, Inc. Second Quarter 2023 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation.

04:05 29 Mar 2024 OMIC

Singular Genomics to Report Second Quarter 2023 Financial Results on August 9, 2023

SAN DIEGO, July 26, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter 2023 after the market close on Wednesday, August 9, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

04:05 29 Mar 2024 OMIC

Singular Genomics to Present at the Goldman Sachs Global Healthcare Conference

SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA.

06:28 29 Mar 2024 OMIC

Singular Genomics Systems, Inc. (OMIC) Q1 2023 Earnings Call Transcript

Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder and CEO Dalen Meeter - CFO Conference Call Participants Tom Stevens - TD Cowen John Sourbeer - UBS Michael Ryskin - Bank of America Operator Greetings. Welcome to the Singular Genomics Systems, Incorporated First Quarter 2023 Earnings Conference Call.

07:07 29 Mar 2024 OMIC

Similar Genomics Systems (OMIC) Reports Q1 Loss, Lags Revenue Estimates

Similar Genomics Systems (OMIC) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.31 per share a year ago.

OMIC Financial details

Company Rating
Neutral
Market Cap
38.07M
Income
-93.33M
Revenue
2.91M
Book val./share
2.43
Cash/share
2.36
Dividend
-
Dividend %
-
Employees
255
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.36
Forward P/E
-0.44
PEG
-0.89
P/S
12.45
P/B
0.16
P/C
0.22
P/FCF
-0.42
Quick Ratio
12.56
Current Ratio
13.64
Debt / Equity
0.42
LT Debt / Equity
0.38
-
-
EPS (TTM)
-1.29
EPS next Y
-1.18
EPS next Q
-0.27
EPS this Y
4.84%
EPS next Y
-8.65%
EPS next 5Y
-40.82%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
133.98%
EPS Q/Q
3.23%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
34.46%
Inst Trans
0.76%
ROA
-32%
ROE
-39%
ROC
-0.37%
Gross Margin
-5%
Oper. Margin
-3855%
Profit Margin
-3459%
Payout
-
Shs Outstand
73.93M
Shs Float
42.18M
-
-
-
-
Target Price
-
52W Range
0.31-1.32
52W High
-
52W Low
-
RSI
50
Rel Volume
0.44
Avg Volume
127.99K
Volume
56.48K
Perf Week
4.36%
Perf Month
-6.07%
Perf Quarter
45.25%
Perf Half Y
30.38%
-
-
-
-
Beta
1.41
-
-
Volatility
0%, 0.03%
Prev Close
0%
Price
0.5142
Change
-1.04%

OMIC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0000.010.04
Net income per share
-0.25-0.41-2.1-1.24-1.3
Operating cash flow per share
-0.23-0.36-1.1-1.22-1.01
Free cash flow per share
-0.25-0.38-1.2-1.31-1.03
Cash per share
0.940.397.213.442.39
Book value per share
-0.5-0.747.153.662.46
Tangible book value per share
-0.5-0.747.153.662.46
Share holders equity per share
-0.5-0.747.153.662.46
Interest debt per share
0.050.150.230.841.05
Market cap
1.27B1.78B543.59M143.01M33.49M
Enterprise value
1.27B1.78B352.44M127.59M92.55M
P/E ratio
-102.96-62.2-5.5-1.62-0.35
Price to sales ratio
000186.9411.51
POCF ratio
-111.47-71.68-10.51-1.64-0.45
PFCF ratio
-104.16-67.91-9.61-1.54-0.45
P/B Ratio
-51.39-34.581.620.550.19
PTB ratio
-51.39-34.581.620.550.19
EV to sales
000166.7831.79
Enterprise value over EBITDA
-106.01-67.47-5.82-1.42-1.07
EV to operating cash flow
-111.2-71.58-6.82-1.46-1.26
EV to free cash flow
-103.9-67.82-6.23-1.37-1.24
Earnings yield
-0.01-0.02-0.18-0.62-2.83
Free cash flow yield
-0.01-0.01-0.1-0.65-2.23
Debt to equity
-0.1-0.180.030.230.42
Debt to assets
0.050.310.030.180.28
Net debt to EBITDA
0.260.093.160.17-0.68
Current ratio
41.787.4751.5719.0110.51
Interest coverage
-751.18-38.35-72.43-122.53-93.37
Income quality
0.920.890.520.960.78
Dividend Yield
000.0100
Payout ratio
-0.2-0.26-0.0400
Sales general and administrative to revenue
00000
Research and developement to revenue
00060.3916.41
Intangibles to total assets
000-0.05-0.06
Capex to operating cash flow
0.070.060.090.070.01
Capex to revenue
000-7.87-0.33
Capex to depreciation
-2.29-2.16-4.29-1-0.13
Stock based compensation to revenue
00017.873.92
Graham number
1.682.6318.3910.118.49
ROIC
0.570.67-0.18-0.25-0.35
Return on tangible assets
-0.26-0.94-0.28-0.26-0.34
Graham Net
-0.54-0.86.852.621.31
Working capital
45.35M23.88M341.02M254.31M173.94M
Tangible asset value
-24.73M-51.56M336.17M275.18M195.33M
Net current asset value
-26.44M-54.49M328.29M200.78M105.77M
Invested capital
-0.1-0.180.030.230.42
Average receivables
08.5K533.5K981.5K1.25M
Average payables
0494K1.39M2.72M2.84M
Average inventory
0-8.5K1.5M10.62M15.9M
Days sales outstanding
000435.61198.61
Days payables outstanding
585.04243.9756.421.43K272.2
Days of inventory on hand
0-9.719708.43K1.43K
Receivables turnover
0000.841.84
Payables turnover
0.621.50.480.251.34
Inventory turnover
0-37.590.380.040.26
ROE
0.50.56-0.29-0.34-0.53
Capex per share
-0.02-0.02-0.1-0.08-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.010.010.010.010.01
Net income per share
-0.27-0.31-0.35-0.31-0.32
Operating cash flow per share
-0.28-0.25-0.28-0.23-0.26
Free cash flow per share
-0.3-0.25-0.28-0.23-0.26
Cash per share
3.423.142.852.612.36
Book value per share
3.643.343.012.722.43
Tangible book value per share
3.643.343.012.722.43
Share holders equity per share
3.643.343.012.722.43
Interest debt per share
0.830.820.811.061.03
Market cap
143.89M87.03M60.18M27.88M33.84M
Enterprise value
128.46M16.35M43.76M71.59M92.9M
P/E ratio
-1.83-0.98-0.59-0.31-0.36
Price to sales ratio
188.09100.85119.1760.3531.31
POCF ratio
-7.22-4.85-3.01-1.66-1.79
PFCF ratio
-6.62-4.81-2.96-1.65-1.75
P/B Ratio
0.550.360.280.140.19
PTB ratio
0.550.360.280.140.19
EV to sales
167.9318.9586.65154.9585.93
Enterprise value over EBITDA
-6.16-0.76-1.87-3.54-4.36
EV to operating cash flow
-6.45-0.91-2.19-4.26-4.91
EV to free cash flow
-5.91-0.9-2.16-4.23-4.81
Earnings yield
-0.14-0.25-0.43-0.8-0.69
Free cash flow yield
-0.15-0.21-0.34-0.61-0.57
Debt to equity
0.230.240.270.390.42
Debt to assets
0.180.190.210.270.28
Net debt to EBITDA
0.743.280.7-2.16-2.77
Current ratio
19.0119.7316.1813.6410.51
Interest coverage
-92.72-97.98-102.23-86.1-88.09
Income quality
0.940.760.780.750.81
Dividend Yield
00000
Payout ratio
-0.020000
Sales general and administrative to revenue
30.790000
Research and developement to revenue
14.0714.172524.2910.81
Intangibles to total assets
-0.05000-0.06
Capex to operating cash flow
0.090.010.020.010.02
Capex to revenue
-2.38-0.19-0.61-0.24-0.36
Capex to depreciation
-1.06-0.09-0.16-0.06-0.24
Stock based compensation to revenue
4.053.575.636.052.49
Graham number
4.744.814.894.324.16
ROIC
-0.06-0.07-0.09-0.08-0.09
Return on tangible assets
-0.06-0.07-0.09-0.08-0.08
Graham Net
2.612.362.051.561.3
Working capital
254.31M233.98M211.74M195.34M173.94M
Tangible asset value
275.18M240.33M218.39M199.03M195.33M
Net current asset value
200.78M181.33M160.1M125.3M105.77M
Invested capital
0.230.240.270.390.42
Average receivables
891K779.5K671.5K2.01M2.46M
Average payables
3.04M2.54M1.98M2.2M2.51M
Average inventory
17.46M17.69M15.76M13.89M13.5M
Days sales outstanding
107.4167.37124.22648.9131.88
Days payables outstanding
353.5220.48297.59415.33151.38
Days of inventory on hand
2.08K1.91K2.16K2.29K794.2
Receivables turnover
0.841.340.720.140.68
Payables turnover
0.250.410.30.220.59
Inventory turnover
0.040.050.040.040.11
ROE
-0.08-0.09-0.12-0.11-0.13
Capex per share
-0.03000-0.01

OMIC Frequently Asked Questions

What is Singular Genomics Systems, Inc. stock symbol ?

Singular Genomics Systems, Inc. is a US stock , located in La jolla of Ca and trading under the symbol OMIC

What is Singular Genomics Systems, Inc. stock quote today ?

Singular Genomics Systems, Inc. stock price is $0.5142 today.

Is Singular Genomics Systems, Inc. stock public?

Yes, Singular Genomics Systems, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap